• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2010 年膀胱癌:我们已经走了多远?

Bladder cancer in 2010: how far have we come?

机构信息

Department of Urology, University of Pitsburgh School of Medicine, 3471 Fifth Avenue, Pittsburgh, PA 15213-3233, USA.

出版信息

CA Cancer J Clin. 2010 Jul-Aug;60(4):244-72. doi: 10.3322/caac.20077. Epub 2010 Jun 21.

DOI:10.3322/caac.20077
PMID:20566675
Abstract

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.

摘要

膀胱癌是美国男性中第四大常见癌症,也是第八大癌症死因。尽管指南有助于治疗,但膀胱癌的治疗艺术,如使用新辅助化疗的决策和膀胱切除术的时机,仍然存在差异。膀胱癌有复发的倾向,随着复发,大量病例进展,这使得早期发现高危患者势在必行。本文综述了膀胱癌的检测、监测和治疗进展。

相似文献

1
Bladder cancer in 2010: how far have we come?2010 年膀胱癌:我们已经走了多远?
CA Cancer J Clin. 2010 Jul-Aug;60(4):244-72. doi: 10.3322/caac.20077. Epub 2010 Jun 21.
2
[Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].[欧洲泌尿外科学会关于肌层浸润性和转移性膀胱癌临床指南的更新]
Actas Urol Esp. 2010 Jan;34(1):51-62.
3
Diagnosis and treatment of bladder cancer.膀胱癌的诊断与治疗。
Am Fam Physician. 2009 Oct 1;80(7):717-23.
4
Selection of treatment for muscle infiltrating transitional cell bladder cancer.肌肉浸润性移行细胞膀胱癌的治疗选择
Arch Esp Urol. 1990;43 Suppl 2:219-22.
5
The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.膀胱切除术以及围手术期使用甲氨蝶呤、长春花碱、阿霉素和顺铂化疗对肌层浸润性膀胱癌患者复发风险及复发模式的影响。
J Urol. 2000 May;163(5):1413-8.
6
Optimal management of the T1G3 bladder cancer.T1G3期膀胱癌的优化管理
Urol Clin North Am. 2005 May;32(2):133-45. doi: 10.1016/j.ucl.2005.02.002.
7
Diagnosis and treatment of bladder cancer: how can we improve?膀胱癌的诊断与治疗:如何改善?
Postgrad Med. 2012 May;124(3):28-36. doi: 10.3810/pgm.2012.05.2545.
8
[Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].[根治性膀胱切除术治疗浸润性膀胱癌的结果,特别提及根据尿流改道类型的预后因素和生活质量]
Ann Acad Med Stetin. 2000;46:217-29.
9
Editorial comment on: HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.关于“HYAL-1透明质酸酶:膀胱癌进展至肌肉浸润和复发的潜在预后指标”的编辑评论
Eur Urol. 2010 Jan;57(1):93-4. doi: 10.1016/j.eururo.2009.03.058. Epub 2009 Mar 31.
10
Bladder cancer.膀胱癌
Curr Opin Oncol. 2006 May;18(3):277-83. doi: 10.1097/01.cco.0000219258.75961.1a.

引用本文的文献

1
Long-term trends in bladder cancer incidence using a harmonized staging variable - A SEER-based study.使用统一分期变量分析膀胱癌发病率的长期趋势——一项基于监测、流行病学和最终结果(SEER)的研究
Cancer Epidemiol Biomarkers Prev. 2025 Jul 11. doi: 10.1158/1055-9965.EPI-25-0210.
2
Urea Transporters and Their Gene Mutations in Diseases.疾病中的尿素转运蛋白及其基因突变
Subcell Biochem. 2025;118:127-140. doi: 10.1007/978-981-96-6898-4_7.
3
Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions.抗体药物偶联物作为膀胱癌的变革者:当前进展与未来方向
Front Immunol. 2025 May 13;16:1591191. doi: 10.3389/fimmu.2025.1591191. eCollection 2025.
4
Bladder cancer biomarkers: current approaches and future directions.膀胱癌生物标志物:当前方法与未来方向。
Front Oncol. 2024 Nov 29;14:1453278. doi: 10.3389/fonc.2024.1453278. eCollection 2024.
5
IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development.IGF2BP3 可防止膀胱癌和发育过程中 HMGB1 mRNA 的降解。
Cell Mol Biol Lett. 2024 Mar 19;29(1):39. doi: 10.1186/s11658-024-00545-1.
6
Identification and preliminary analysis of hub genes associated with bladder cancer progression by comprehensive bioinformatics analysis.通过综合生物信息学分析鉴定膀胱癌进展相关的枢纽基因并进行初步分析。
Sci Rep. 2024 Feb 2;14(1):2782. doi: 10.1038/s41598-024-53265-z.
7
m6A Methylation-Mediated Stabilization of LINC01106 Suppresses Bladder Cancer Progression by Regulating the miR-3148/DAB1 Axis.m6A甲基化介导的LINC01106稳定通过调控miR-3148/DAB1轴抑制膀胱癌进展。
Biomedicines. 2024 Jan 5;12(1):114. doi: 10.3390/biomedicines12010114.
8
Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.三周期与四周期新辅助化疗治疗肌层浸润性膀胱癌的系统评价与荟萃分析。
Ann Med. 2023;55(2):2281654. doi: 10.1080/07853890.2023.2281654. Epub 2023 Nov 14.
9
ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/β-catenin pathway.ZEB1 介导的 circNIPBL 的生物发生通过 Wnt/β-连环蛋白通路维持膀胱癌的转移。
J Exp Clin Cancer Res. 2023 Aug 2;42(1):191. doi: 10.1186/s13046-023-02757-3.
10
TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology.TRAIL 介导的膀胱癌信号通路:肿瘤医学中基于 TRAIL 的治疗的临床疗效的实现。
Med Oncol. 2023 Jul 11;40(8):236. doi: 10.1007/s12032-023-02078-7.